Shots:

• Almac Diagnostic and Queen’s University validate a test to decide the chemotherapy to be used for early-stage esophageal cancer to remove the tumor- improve prognosis and QoL
• The focus of the collaboration is to bring personalized therapies for esophageal cancer. Additionally- Almac Diagnostic has developed DNA Damage Immune Response (DDIR) Signature to personalize chemotherapy for breast cancer
• The test increases the molecular understanding of each patient’s cancer and enables the clinicians to decide the right chemotherapy to shrink the tumor

Ref: Almac Diagnostic | Image: Glassdoor